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An overview of the complex biological effects of expanding adipose tissue
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Abstract
Obesity has a more complex biology than previously thought. Feeding behaviour is regulated 
via a integrative circuit of afferent input from the stomach,  the pancreas and the intestines via 
hormonal influences and the vagal nerve, which affect hypothalamic nuclei. This will lead to 
satiety and inhibition of hunger combined with other effects such as energy expenditure and 
growth promoting effects.  Moreover, upon sufficient caloric intake, triglycerides are taken up 
in adipocytes, which in their turn will produce more leptin which inhibits hypothalamic nuclei 
and which will add to these hypothalamic effects. It has been suggested that more macrophages 
enter the adipose tissue which would alter adipocyte secretion. Adipocytes are now known to 
produce an array of proteins with hormonal effects calledadipo(cyto)kines. In obesity, many 
of these adipokines are produced in substantially higher amounts with potentially deleterious 
effcets notably on the risk of atherosclerosis, type 2 diabetes and cancer.
___________________________________________________________________________
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INTRODuCTION
Many countries now see a rapidly expanding 
“pandemic” of obesity.
While this started  mainly in the Western 
world, since some 20 years virtually all 
countries now see their populations literally 
growing fatter.
The causes for this are more complex than 
was initially thought.
A major concern has become the development 
of “visceral obesity” that is the phenomenon 
that adipose tissue has enlarged around the 
“viscera” i.e. within the abdomen. 
Visceral obesity may lead to larger risks for 
a number of diseases, notably cardiovascular 
(atherosclerotic) disease, diabetes mellitus, 
and various forms of cancer (1).
Although the biology behind this is still a 
matter of intense research, the complexity of 
this becomes gradually apparent. The unique 
position of visceral fat as to the portal vein 
circulation has led to intense research into the 
relationship of visceral fat and liver function 
and more generally to the “endocrinological” 
role of visceral fat tissue.
Fat tissue is now known not only to act 
as storage pool for calories in the form of 
triglyceride, but also to secrete a number 
of proteins which act as cytokines at distal 
sites, known as adipocytokines or adipokines. 
Although obesity is a recent phenomenon, 
adipocytokines date back over many millions 
of years and are present in all mammals and 
even other species.
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BIOlOGy Of ADIPOCyTES
Adipose tissue exists mainly of adipocytes, 
which are formed from precursor cells, so 
called pre-adipocytes . Adipocytes can rapidly 
take up fatty acids (FA) and can store fat is 
triglycerides.
FA circulate in the plasma mainly in the form 
of triglycerides,bound to Very Low Density 
Lipoproteins (VLDL) and chylomicrons. 
Upon activation by insulin, Lipoprotein Lipase 
(LPL) located in the vascular tissue will exert 
a lipolytic effect on VLDL-bound triglyceride, 
forming glycerol and three molecules of FA. 
FA’sare then taken up into the adipocyte by 
Fatty Acid Binding Proteins (FABP) which 
are located at the cell surface.
Within the adipocyte, FA’s and glycerol can 
form triglyceride,again under stimulation of 
insulin.Upon uptake of fat, adipocytes become 
larger , but obesity will not induce further 
development of preadipocytes to adipocytes.
Inversely, adipocyte triglyceride can rapidly 
undergo lipolysis in which the FA’s and 
glycerol are formed; FA’s can then leave the 
adipocyte. Lipolysis occurs by enzymatic 
effects of adipose triglyceride lipase 
(ATGL), hormone sensitive lipase (HSL) and 
monoglyceride lipase (2). This process is under 
stimulatory influence of (nor-)epinephrine by 
virtue of the activation of hormone sensitive 
lipase (HSL) (3); insulin is notable in that it 
has a strong inhibitory effect on HSL and thus 
on lipolysis. The latter inhibitory mechanism 
underlines actually the weight losing effect of 
a calorie-restricted diet:caloric restriction will 
lead to less insulin production ; thereby less 
inhibition of lipolysis ensues.
Interestingly, a slight increase in size will 
induce adipocytes to produce larger quantities 
of most of its proteins. In apparent contrast 
to the situation of obesity, leptin’s major 
physiological effects are notable when 
adipocytes are small.
Adipocytes are now known to produce an 
array of adipocytokines with effects not only 
on appetite and energy expenditure (leptin) 
but also on the vasculature (adiponectin, 
visfatin, resistin, omentin, chemerin, apelin), 
the immune system (interleukin-6) or have 
effects on inflammation (Tumor Necrosis 
Factor-alpha (TNF-alpha), adipsin) (4). Many 
adipokines may have a role in cell division 
(leptin, interleukins).
The roles of adiponectin and the effects of 
leptin for food intake will first be described, 
followed by the influences of other organs on 
food intake.
Adiponectin
Adiponectin is produced by adipose tissue 
and skeletal muscle. While larger adipocytes 
will produce larger quantities of most 
adipocytokines, the production of adiponectin 
is lower in larger adipocytes. Adiponectin has 
anti-inflammatory actions in macrophages via 
inhibition of nuclear factor kappa-light chain 
enhancer of B cells (NF-kB) (5). A similar 
inhibition may also have an anti-atherogenic 
effect in endothelial cells. By virtue of its effect 
on endothelial nitric oxide synthase (eNOS), 
which regulates the production of nitric oxide 
(NO), adiponectin may diminish proliferation 
of vascular smooth muscle cells. Some 
studies point also to a role for adiponectin 
in myocardial remodeling protecting the 
myocardium from injury (6).
Adiponectin may increase insulin sensitivity, 
fatty acid oxidation and inhibit hepatic 
gluconeogenesis. These protective effects 
(anti-atherogenic, anti-diabetic, anti-
inflammatory) make adiponectin a” good” 
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adipokine. It is of particular note that since 
adipocytes become larger in obesity, they 
produce less adiponectin possibly adding 
to the augmented risk of obese subjects for 
atherosclerosis and diabetes.
leptin and food intake
Leptin is exclusively produced from 
adipocytes.Its production is regulated over 
the course of weeks. Plentitude of food intake 
will lead to increased production of leptin by 
the (enlarged) adipocytes. 
Leptin acts on leptin receptors present in 
various tissues (7). Upon binding with leptin, 
leptin receptors present in the hypothalamus 
will lead to activation of the melanocortin 4 
receptor (MC4) which will decrease hunger 
(with reduction of food intake) and at the 
same time will lead to expenditure of energy. 
Leptin will further diminish neuropeptide Y 
(NPY) in arcuate nucleus cells, which will 
then suppress hunger.
In addition, leptin receptors in the 
hypothalamus are nicely situated to also 
influence pituitary function (7,8). Leptin can 
stimulate gonadotrophin production which 
activates gonadal function. Upon continued 
food intake , increasing levels of leptin will 
then enable the animals gonadal function 
and ultimately its breeding. Similarly, leptin 
appears to influence growth hormone and 
possibly also Thyrotropin Releasing Hormone 
(TRH) and thereby Thyroid Stimulating 
Hormone (TSH) levels and thyroidal 
function. This constellation would lead to the 
proposition that feeding itself will activate 
in the animal a complex hormonal interplay 
ultimately leading to growth and procreation.
HORMONAl RElATIONS BETwEEN 
OTHER ORGANS AND fOOD INTAKE
Stomach
GhrelinInterestingly, the effects of leptin 
are largely opposed by gastric production 
of ghrelin, a protein which is produced 
under circumstances of hunger. Ghrelin can 
stimulate the release of Growth Hormone 
(GH), hence its name. Upon binding to 
specific receptors in the hypothalamus, 
Ghrelin stimulates Neuropeptide Y (NPY) 
release and induces food intake (9). It was 
originally thought that the stomach would 
secrete ghrelin simply because the stomach 
was empty and therefore the person was 
hungry. The thus secreted ghrelin would then 
stimulate the person via the hypothalamus to 
go and eat. However, it now appears that in 
humans this relationship is more complex and 
that the simple knowledge of a person that “it 
is time to eat” may be sufficient for cerebral 
stimulation of the stomach to secrete more 
ghrelin, which indeed in turn will activate the 
hypothalamus to make the person feel hungry. 
Therefore, the clinical importance of ghrelin 
is still under debate.
Pancreas
Insulin secretion  Insulin is secreted in low 
amounts during the fasting state by B cells 
in the pancreas islets. Upon eating insulin is 
secreted in larger amounts, both due to the 
effects of swallowing and the stimulation of 
food on the intestines and by the mere effect 
of the rise in plasma glucose. Insulin will then 
lead to decreases in hepatic glucose production 
and uptake of glucose and formation of 
glycogen in muscle and adipose tissue.
Interestingly, insulin is now known to have 
more effects:  it has cell nucleus effects leading 
to changes in protein production and even 
mitosis in various tissues. Moreover, insulin 
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has multiple effects on the hypothalamus 
leading to enhancing satiety after a meal , and 
inhibition of hunger (10). Indeed , intranasal 
insulin administration reduces body weight 
in men (but not in women) (11). Thus, 
insulin appears to have leptin-like actions 
on hypothalamic centers although its time 
course is possibly more rapid. Indirectly, it 
may enhance energy expenditure possibly via 
enhanced sympathetic tone. 
The gut
The presence of food in the intestines will 
lead to production of gastric inhibitory 
polypeptide also known as glucose-
independent insulinotropic polypeptide 
(GIP) and glucagon-like peptide 1 (GLP1) 
which will activate the B-cells via specific 
cell receptors to produce and secrete insulin 
especially at times that plasma glucose levels 
are (slightly) elevated (12).
GLP1 and GIPGLP1 has multiple effects 
presumably on cardiac tissue and especially 
on food intake. In rodents, GLP1 diminishes 
food intake by activation of specific 
receptors on hypothalamic centers by effects 
reminiscent of leptin. However, in humans 
GLP1 is metabolized to inactive metabolites 
within minutes by dipeptidyl peptidase 4 
(DPP4). In humans the effects of GLP1 on 
food intake have been suggested to be indirect 
via stimulation of the autonomic nervous 
system especially the afferent branches of 
the vagal nerve (13). However, subcutaneous 
administration of  analogues of GLP-1, that 
are not readily metabolized by DPP4, are 
effective in reducing hunger and consequently 
in reducing food intake presumably by direct 
hypothalamic effects.
In rodents GIP has also an effects on the 
hypothalamus leading to satiety and less 
hunger.
In the lower intestines Peptide YY (PYY) is 
also released in response to food and , just as 
GLP1, notably in response to protein (14).
Taken together the leptin pathways imply a 
useful feedback of adipocytes on appetite and 
food intake. Various hormonal and neuronal 
effects from the gut further influence food 
intake. They also enable the animal to expand 
energy, and appear to fulfill roles in enabling 
the animal to grow and to breed under 
circumstances with sufficient food.
ROlE Of INflAMMATION IN 
ExPANDING ADIPOSE TISSuE 
Normal fat tissue contains a low amount of 
inflammatory cells, notably macrophages 
of the M2 type and eosinophils. In obesity, 
these cells are relatively scarce, while other 
inflammatory cells predominate, notably M1-
macrophages, neutrophils , lymphocytes, 
mast cells and others (15). This apparently 
leads to augmented secretion of cytokines, 
among which Tumor Necrosis Factor –alpha 
(TNF-α), Interleukin-6 (IL-6) and others, 
which have been reported to impair insulin 
signaling.
Visceral fat and subcutaneous tissue express 
a large number of genes in an identical 
manner. However, subtle differences exist (1), 
with preponderance of leptin production in 
subcutaneous fat tissue, while no differences 
exist in TNF-alpha; complement factors, 
angiotensinogen and others are produced 
predominantly in visceral tissue. Many of 
the deleterious effects of obesity seem to 
relate mainly to the development of visceral 
adiposity.
BIOlOGICAl  IMPACT  Of  OBESITy
Obesity has a slowly evolving effect on 
alarge number of systems in mammals. It has 
gradually become clear that obesity increases 
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the risk of atherosclerosis, type 2 diabetes 
mellitus (Type 2 DM) and of certain types of 
cancer.These three disorders will be described 
only briefly, since an elaborate review of these 
complex disorders is outside the scope of this 
overview.
Atherosclerosis
Epidemiological studies have concluded to 
a augmented risk for atherosclerotic disease 
for obese people (1). However, the largest 
risk seems to relate to visceral adiposity, 
that is the existence of adiposity around the 
“viscera” within the abdomen, as opposed 
to subcutaneous fat. Atherosclerosis is a 
complex disease with disturbances in the 
arteries among which in the intima media . 
A large number of mechanisms is involved, 
including macrophage activation in the arterial 
wall, enhanced inflammatory changes, pro-
thrombotic changes etc.
Adipokines have multiple effects which 
can augment the atherosclerotic process.
For example, leptin has an NO-dependent 
vasodilatory effect but it can also upregulate 
endothelin-1 , a vasoconstrictor (16). It 
has also been proposed to lead to cellular 
changes in vascular cells. Resistin has been 
proposed to activate endothelin (15), and to 
have multiple effects leading to endothelial 
dysfunction and possibly proliferative effects 
on the vasculature (6). Adiponectin has been 
proposed to exert anti-atherosclerotic effects 
via its inhibitory effects on TNF-alpha in 
the vascular wall. Unfortunately, in obesity, 
less adiponectin is produced in adipocytes. 
Visfatin is also produced less in obesity.
In obesity, adipocytes grow larger and produce 
larger amounts of most of the adipokines. 
It has been proposed that this is related to 
hypoxia within the adipose cell (16). 
Dyslipidemia Obesity is associated with 
disturbances in plasma lipids, with a notable 
increase in Low Density Lipoprotein 
cholesterol (LDL-cholesterol) and plasma 
triglycerides, and a decrease in High Density 
Lipoprotein cholesterol (HDL-cholesterol) 
especially in insulin resistant subjects. 
Presumably, the underlying insulin resistance 
leads to slightly elevated lipolysis with 
production of fatty acids in adipose tissue. 
Upon uptake in the liver, fatty acids will be 
bound to triglyceride. In the liver this is process 
is related to the production of cholesterol and 
its binding lipoprotein (Apo-B 100); this leads 
to Very-Low-Density-Lipoprotein (VLDL) 
formation. VLDL is transported into the 
blood, and it can release its cholesterol and 
its triglycerides in the vessel wall, potentially 
leading to atherosclerosis.
Hypertension .Angiotensinogen and leptin 
have been proposed to lead to hypertension. 
Indeed, although obesity itself clearly relates 
to hypertension, leptin-deficient humans 
(who are very obese) are not hypertensive. 
Leptin can augment sympathetic tone and can 
upregulate  Na/K ATP-ase in the kidney. Large 
adipocytes produce more angiotensinogen, 
which would activate aldosterone and thereby 
lead to hypertension.
Insulin resistance
Insulin has a number of secondary effects: 
upon activation of the insulin receptor, 
autophosphorylation of the receptor activates 
Insulin Receptor Substrate-1 (IRS-1), which 
in its turn will phosphorylate subsequent 
molecules, Phospho- Inositol-3 phosphate 
Kinase (PI3-Kinase) leading to activation of 
Akt, ultimately leading to transcription of 
other factors at the DNA level, which will 
lead to production of various protein involved 
in diverse cellular processes as glycogen 
formation, (inhibition of) gluconeogenesis, 
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and to stimulation of glucose uptake. Insulin 
will also activate IRS-2. Via separate pathway 
of activating Mitogen Activating Protein 
Kinase (MAPK), activation of the IRS-1 will 
also lead to processes involved in expression 
of other genes notably involved in cellular 
growth and mitosis. 
The activity of IRS1 is of major importance 
for overall insulin signaling. IRS-1 activity 
can be decreased by serine phosphorylation by 
Protein Kinase C (PKC), C-JunKinase (JNK), 
mammalian target of rapamycin (m-Tor), 
Suppressor of cytokine signaling-3 (Socs3)and 
others (17). This will decrease phosphorylation 
of PI-3K and activateproteasome dependent 
degradation.
Although the precise mechanisms of the 
occurrence of insulin resistance is still  a 
matter of intense research, Free Fatty Acids 
(FFA), interleukin -6 and TNF-alpha have 
been proposed as causing insulin resistance 
by inducing transcription of factors leading 
to serine phosphorylation of IRS-1(and 
possibly IRS-2) at sites which will decrease 
the activation of down-stream molecules. 
The (separate) pathway leading to activation 
of mitogen activated protein kinase (MAPK) 
and cellular growth is presumably less or not 
involved in the process of insulin resistance. 
This has led to the hypothesis that under states 
of insulin resistance the MAPK dependent 
mechanisms have deleterious effects, for 
example in the myocardium (18). Similarly, it 
has been proposed that vasoconstrictor effects 
of insulin is regulated by MAPK dependent 
signaling while nitric oxide (NO) dependent 
vasodilator effects are regulated via PI-3K. 
In states of insulin resistance the MAPK 
effects would predominate possibly leading 
to endothelial dysfunction (19).
Type 2 Diabetes
Obesity is strongly associated with Type 
2 diabetes.Type 2 diabetes ensues as a 
consequence of the combination of insulin 
resistance and pancreas beta cell failure 
(20). The above mentioned mechanisms for 
the development of insulin resistance are 
certainly of importance for the development 
of diabetes. During the development of type 2 
diabetes beta cell mass is probably diminished 
in part by apoptosis (21). 
It is now suspected that a number of adipokines 
have deleterious effects in beta-cells. 
Leptin itself can augment insulin secretion. 
There is conflicting evidence regarding its 
potential to affect B cell apoptosis. On one side 
leptin has been shown to decrease uncoupling 
protein 2 (UCP2) in Bcells which would 
decrease apoptosis, but othershave not found 
an effect on apoptosis (22). However, leptin 
has multiple effects on gene transcription in 
various cell types both via Janus Kinase /
Signal Transducer and Activator Transcription 
(JAK/STAT) and MAPK/extracellular signal-
regulated kinase (ERK) pathways which may 
have more subtle effects in apoptosis and/or 
in B cell function. 
Fatty acids, among which notably palmitate, 
have been shown to be deleterious for B cells 
and to be able to cause apoptosis. Adiponectin 
has been proposed to diminish the deleterious 
effects of palmitate . In its turn, palmitate 
appears to lower adiponectin receptor 2 
mRNA. Adiponectin may also have effects 
on gene transcription via ERK pathways (22). 
Others have proposed that adiponectin (and 
leptin) increase proliferation of B cells.
TNF-alpha is able to induce apoptosis in B 
cells (22) either directly or possibly also via 
augmenting amylin expression; amylin has 
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been proposed to lead to accumulation of 
amyloid in islets.
Although a possible role of visfatin is far 
from clear, it now appears that visfatin may 
stimulate B cell proliferation; it may have 
additional effects  possibly via gene regulation 
of PDX1 and the insulin gene (22).  Visfatin 
is notable since its production is decreased in 
obesity and therefore its potential beneficial 
effects on B cells might be of less importance 
in obesity.
Cancer
Obesity is associated with a markedly 
increased risk for a number of cancer types 
,such as colon, esophageal, breast, uterine, 
prostate and other cancers. In view of the 
marked hyperinsulinemia associated with 
insulin resistance, insulin is suspected to play 
a major role. Indeed, insulin has proliferative 
and anti-apoptotic effects in various tissues. 
Whether this effect is via the actual insulin 
receptor or via the Insulin-like Growth Factor 
–I (IGF-1) receptor is so far less clear; insulin 
can actually be bound to both receptor types 
(23). The growth promoting properties of 
IGF-1 are complex, since IGF-1 is bound to a 
number of binding proteins, the levels of which 
are partly dependent on plasma insulin.
A number of studies have looked into the 
potential role of leptin for breast cancer. 
Leptinappears to augment estrogen production 
and expression , and it has a proliferative effect 
on breast tumour cells (23,24). By its MAPK 
and STAT signaling effects leptin is relevant 
for cell proliferation  and differentiation (23).
Adiponectin has been proposed to protect 
against carcinogenesis by its insulin sensitizing 
effects (counteracting hyperinsulinemia), and 
by inactivating MAPK.
Plasminogen activator inhibitor-1 (PAI-1) 
which is also augmented in obesity has also 
been hypothesized to relate to cancer by 
promoting tumour growth and/or by effects 
on the vasculature such as adhesion and 
angiogenesis (22). Although more adipokines 
have been named as potentially involved in 
tumorigenesis, more research will be needed 
before this would become clearer (22).
CONCluSION
Recent years have seen the exciting discovery 
of the fundamental role of fat tissue hormonal 
regulation of food intake, satiety, and energy 
expenditure, as exemplified by the role of leptin. 
This has subsequently led to the discovery 
of several of hormones from other organs 
, especially the gut , with important effects 
in the regulation of food intake. Expanding 
adipose tissue, as is seen in obesity, has now 
been proposed to be under the influence of 
inflammatory cells such as macrophages. 
This leads presumably to production of 
deleterious substances such as TNF-alpha, 
interleukins and others. Several adipokines 
may be involved in the development of insulin 
resistance. Moreover, in obesity, adipocytes 
produce high amounts of deleterious 
adipokines that may have deleterious effects 
on the risk of atherosclerosis, type 2 diabetes 
and cancer. Obese subjects are generally 
hyperinsulinemic in response to the prevailing 
insulin resistance. It has been suggested that 
insulin may have growth proliferative effects 
involved in tumour growth.  Unfortunately, 
in obesity lower amounts of adiponectin are 
produced; adiponectin may have protective 
effects both against the development of 
atherosclerosis, and cancer and possibly type 
2 diabetes. 
Legends
Figure 1. A schematic representation of the 
effects of various hormones influencing 
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feeding  behaviour.
Figure 2. Hypothalamic effects of leptin 
on feeding behaviour are associated with 
other effects notably on energy expenditure, 
and complex interactions with growth, and 
procreation.
Figure 3 .Insulin resistance: Effects of 
adipokines on insulin signaling
Figure 4.  Schematic representation of potential 
effects of adipokines on atherosclerosis, 
cancer and type 2 diabetes mellitus
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